Tenosynovial Giant Cell Tumors Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Daiichi Sankyo Co., Ltd., Deciphera Pharmaceuticals LLC, Abbisko Therapeutics Co, Ltd, AmMax Bio Inc., SynOx Therapeutics Li

DelveInsight's "Tenosynovial Giant Cell Tumors Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Tenosynovial Giant Cell Tumors, historical and forecasted epidemiology as well as Tenosynovial Giant Cell Tumors market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Tenosynovial Giant Cell Tumors Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Tenosynovial Giant Cell Tumors Market Forecast. Click here to stay ahead in healthcare innovation @ Tenosynovial Giant Cell Tumors Market Size- https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Tenosynovial Giant Cell Tumors Market Size Report
• In March 2025, Daiichi Sankyo Co. Ltd announced a study will be conducted in Japan and will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of pexidartinib in adult participants with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitation and not amenable to improvement with surgery.
• In March 2025, Deciphera Pharmaceuticals, LLC organized a phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the tumor is not an option.
• In March 2025, SynOx Therapeutics Limited announced a study consists of two parts. In Part 1, eligible subjects will be assigned in a 2:1 ratio to receive either emactuzumab or matching placebo in a double-blind fashion, that will be administered in total 5 times as an intravenous (i.v.) infusion once every 2 weeks. This will be followed by an observation period of 3 months leading to a total duration of 24 weeks in Part 1.
• In 2023, the total Tenosynovial Giant Cell Tumors incident population in the United States was ~15,000 cases, which as per DelveInsight's estimates, is expected to increase by 2034.
• It was estimated that there were nearly ~14,600 cases of TGCT in EU4 countries and the UK in 2023. Germany accounted for the highest number of cases.
• It was found that in 2023, the total Tenosynovial Giant Cell Tumors incident population of localized in the United States had ~5,000 males and ~8,000 females, which as per our estimates, is expected to increase during our forecast period.
• The total Tenosynovial Giant Cell Tumors incident cases in the 7MM were around ~34,000 cases in 2023 out of which the highest prevalent cases of this disease were seen in the United States.
• The leading Tenosynovial Giant Cell Tumors Companies such as Daiichi Sankyo Co., Ltd., Deciphera Pharmaceuticals LLC, Abbisko Therapeutics Co, Ltd, AmMax Bio Inc., SynOx Therapeutics Limited, and others.
• Promising Tenosynovial Giant Cell Tumors Therapies such as Emactuzumab, AMB-05X, Nilotinib, Vimseltinib, Pimicotinib(ABSK021), Pexidartinib, and others.

Navigate the complexities of the Tenosynovial Giant Cell Tumors Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Tenosynovial Giant Cell Tumors Market Forecast. Click here to get more insights @ Tenosynovial Giant Cell Tumors Treatment Market- https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Tenosynovial Giant Cell Tumors Epidemiology Insights in the 7MM
• Tenosynovial Giant Cell Tumors Incident Cases
• Tenosynovial Giant Cell Tumors Growth Pattern-specific Incident Cases
• Tenosynovial Giant Cell Tumors Gender-specific Incident Cases of Localized
• Gender-specific Incident Cases of Diffuse Tenosynovial Giant Cell Tumors
• Tumor Localization of Localized Tenosynovial Giant Cell Tumors
• Tumor Localization of Diffuse Tenosynovial Giant Cell Tumors in the US
• Total Treated Cases of Tenosynovial Giant Cell Tumors in the US

Delve deep into the Tenosynovial Giant Cell Tumors Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Tenosynovial Giant Cell Tumors Market Forecast. Click here to shape the future @ Tenosynovial Giant Cell Tumors Prevalence- https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Tenosynovial Giant Cell Tumors Marketed Therapies
• TURALIO (pexidartinib): Daiichi Sankyo
TURALIO (pexidartinib, formerly PLX3397) is an orally administered small molecule tyrosine kinase inhibitor that targets colony-stimulating factor 1 receptor (CSF1R), KIT proto-oncogene receptor tyrosine kinase (KIT), and FMS-like tyrosine kinase 3 (FLT3) harboring an internal tandem duplication (ITD) mutation.

Tenosynovial Giant Cell Tumors Emerging Drugs Profile

• DCC-3014 (vimseltinib): Deciphera Pharmaceuticals
DCC-3014 (vimseltinib) is an orally administered, potent, and highly-selective switch-control kinase inhibitor of the colony-stimulating factor 1 receptor (CSF1R) with potential antineoplastic, macrophage checkpoint-inhibitory and immunomodulating activities. In November 2021, vimseltinib was granted Fast Track Designation (FTD) by the US FDA for the treatment of patients with TGCT who are not amenable to surgery.

• Emactuzumab: SynOx Therapeutics (Celleron Therapeutics)
Emactuzumab is a potent, specific inhibitor of CSF-1R, and data generated to date show its potential as a therapeutic platform targeting serious macrophage-driven inflammatory, fibrotic, and neovascular diseases. Currently, SynOx Therapeutics is conducting a Phase III TANGENT (NCT05417789) trial to study the drug for treating patients with localized or diffuse TGCT where surgical removal of the tumor is not viewed as an option. In April 2024, SynOx Therapeutics announced the closing of a USD 75 million Series B financing. The financing was co-led by Forbion, HealthCap and new investor Bioqube Ventures. The fund will be used to generate registrational Phase III clinical and CMC data for emactuzumab for the treatment of Tenosynovial Giant Cell Tumour (TGCT).

Unlock insights into the Tenosynovial Giant Cell Tumors Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Tenosynovial Giant Cell Tumors Market Forecast. Click here @ Tenosynovial Giant Cell Tumors Market Drivers and Barriers- https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Tenosynovial Giant Cell Tumor Market Outlook
Systemic Therapies are the most commonly used intervention for patients with giant cell tumors. These off-label drugs help combat adverse consequences of surgery, such as recurrence, resulting in a less invasive approach that results in tumor shrinkage and, most importantly, helps in symptomatic improvement in the patients. The molecular pathogenesis of TGCT/PVNS helped introduce targeted agents that inhibit CSF1R for treating tumors. Small molecule inhibitors, such as imatinib and sunitinib, can inhibit CSF1R activation at several therapeutic concentrations.

Tenosynovial Giant Cell Tumors Drugs Uptake
• Vimseltinib: Deciphera Pharmaceuticals
It is an orally administered, potent, and highly-selective switch-control kinase inhibitor of the colonystimulating factor 1 receptor (CSF1R) with potential antineoplastic, macrophage checkpoint-inhibitory and immunomodulating activities It has demonstrated encouraging preliminary efficacy and safety data in patients with TGCT and is currently being evaluated in Phase III clinical trial (MOTION).

• Emactuzumab: SynOx Therapeutics
The monoclonal antibody emactuzumab is a potent, specific inhibitor of CSF-1R and data generated to date show its potential as a therapeutic platform targeting serious macrophage-driven inflammatory, fibrotic and neovascular diseases. The CSF-1 receptor, via its binding to two regulatory cytokines, CSF-1 and IL-34, is critically involved in the regulation of macrophages and related cells in multiple biological processes across many organ systems, making it an attractive target with broad therapeutic applications.

Gain a strategic edge in the Tenosynovial Giant Cell Tumors Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Tenosynovial Giant Cell Tumors Market Forecast. Click here to lead in advancements @ Tenosynovial Giant Cell Tumors Clinical Trials Assessment- https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Tenosynovial Giant Cell Tumors Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Tenosynovial Giant Cell Tumors Companies- Daiichi Sankyo Co., Ltd., Deciphera Pharmaceuticals LLC, Abbisko Therapeutics Co, Ltd, AmMax Bio Inc., SynOx Therapeutics Limited, and others.
• Tenosynovial Giant Cell Tumors Therapies- Emactuzumab, AMB-05X, Nilotinib, Vimseltinib, Pimicotinib(ABSK021), Pexidartinib, and others.
• Tenosynovial Giant Cell Tumors Market Dynamics: Tenosynovial Giant Cell Tumors Market drivers and Tenosynovial Giant Cell Tumors Market Barriers
• Tenosynovial Giant Cell Tumors Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Tenosynovial Giant Cell Tumors Unmet Needs, KOL's views, Analyst's views, Tenosynovial Giant Cell Tumors Market Access and Reimbursement

Discover the latest advancements in Tenosynovial Giant Cell Tumors Treatment by visiting our website. Stay informed about how we're transforming the future- https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Tenosynovial Giant Cell Tumors Market Report Introduction
3. Tenosynovial Giant Cell Tumors Market Overview at a Glance
4. Executive Summary of Tenosynovial Giant Cell Tumor
5. Key Events
6. Tenosynovial Giant Cell Tumors Epidemiology and Market Methodology
7. Tenosynovial Giant Cell Tumors Disease Background and Overview
8. Tenosynovial Giant Cell Tumors Epidemiology and Patient Population
9. Tenosynovial Giant Cell Tumors Patient Journey
10. Tenosynovial Giant Cell Tumors Marketed Therapies
11. Tenosynovial Giant Cell Tumors Emerging Therapies
12. Tenosynovial Giant Cell Tumor: The 7MM Analysis
13. Tenosynovial Giant Cell Tumors Market Access and Reimbursement
14. KOL Views
15. SWOT Analysis
16. Unmet Needs
17. Appendix
18. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

List of Top Selling Market Research Reports in 2025

Autosomal Dominant Polycystic Kidney Disease Market- https://www.delveinsight.com/report-store/autosomal-dominant-polycystic-kidney-disease-market
Familial Lipoprotein Lipase Deficiency Pipeline- https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-pipeline-insight
Frontotemporal Dementia Pipeline- https://www.delveinsight.com/report-store/frontotemporal-dementia-pipeline-insight
Human Papillomavirus-positive Oropharyngeal Cancer Market- https://www.delveinsight.com/report-store/human-papillomavirus-positive-oropharyngeal-cancer-market
Moderate And Severe Chronic Kidney Disease Market- https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market
Monoclonal Gammopathy Of Undetermined Significance Market- https://www.delveinsight.com/report-store/monoclonal-gammopathy-of-undetermined-significance-market
Myopia Treatment Devices Market- https://www.delveinsight.com/report-store/myopia-treatment-devices-market
Myotonic Dystrophy Market- https://www.delveinsight.com/report-store/myotonic-dystrophy-market
Neurodermatitis Market- https://www.delveinsight.com/report-store/neurodermatitis-market
Osteochondrodysplasia Market- https://www.delveinsight.com/report-store/osteochondrodysplasia-market
Peptic Ulcer Hemorrhage Market- https://www.delveinsight.com/report-store/peptic-ulcer-hemorrhage-market
Perivascular Epithelioid Cell Tumor Market- https://www.delveinsight.com/report-store/perivascular-epithelioid-cell-tumor-market
Plasmodium Vivax Malaria Market- https://www.delveinsight.com/report-store/plasmodium-vivax-malaria-market
Thymidine Kinase 2 Deficiency Market- https://www.delveinsight.com/report-store/thymidine-kinase-2-deficiency-tk2d-market
Xlinked Severe Combined Immunodeficiency Market- https://www.delveinsight.com/report-store/xlinked-severe-combined-immunodeficiency-scid-market
Chagas Disease Market - https://www.delveinsight.com/report-store/chagas-disease-market
Diabetes Insipidus Market- https://www.delveinsight.com/report-store/diabetes-insipidus-market
Geographic Atrophy Market- https://www.delveinsight.com/report-store/geographic-atrophy-ga-market
Peanut Allergy Market Report- https://www.delveinsight.com/report-store/peanut-allergy-market
Postherpetic Neuralgia Market- https://www.delveinsight.com/report-store/postherpetic-neuralgia-market
Pouchitis Market- https://www.delveinsight.com/report-store/pouchitis-market
Presbyopia Market- https://www.delveinsight.com/report-store/presbyopia-market
Prostate Cancer Market- https://www.delveinsight.com/report-store/prostate-cancer-market-insight
Refractory Metastatic Melanoma Market- https://www.delveinsight.com/report-store/refractory-metastatic-melanoma-market
Rubella Market- https://www.delveinsight.com/report-store/rubella-market
Smoking Cessation And Nicotine Addiction Market- https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
Systemic Inflammatory Response Syndrome Market- https://www.delveinsight.com/report-store/systemic-inflammatory-response-syndrome-market
Systemic Inflammatory Response Syndrome Market Insights- https://www.delveinsight.com/report-store/systemic-inflammatory-response-syndrome-market
Uveal Melanoma Market- https://www.delveinsight.com/report-store/ocular-melanoma-market
Wiskott-aldrich Syndrome Market- https://www.delveinsight.com/report-store/wiskott-aldrich-syndrome-market
Adult T-cell Leukemia-lymphoma Market- https://www.delveinsight.com/report-store/adult-t-cell-leukemia-lymphoma-market
Artificial Disc Market- https://www.delveinsight.com/report-store/artificial-disc-market
Asperger Syndrome Market- https://www.delveinsight.com/report-store/asperger-syndrome-market
House Dust Mite Allergy Market- https://www.delveinsight.com/report-store/house-dust-mite-allergy-market
Immune Thrombocytopenia Market- https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market
Keloid Market- https://www.delveinsight.com/report-store/keloid-market
Pcsk9 Market- https://www.delveinsight.com/report-store/pcsk9-inhibitors-psck9i-market
Peripheral Nerve Repair Devices Market- https://www.delveinsight.com/report-store/peripheral-nerve-repair-devices-market
Sarcopenia Market- https://www.delveinsight.com/report-store/sarcopenia-market
Skin Neoplasm Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Vascular Imaging Devices Market- https://www.delveinsight.com/report-store/vascular-imaging-market-market
Venous Ulcer Market- https://www.delveinsight.com/report-store/venous-leg-ulcer-market
Cardiogenic Shock Market- https://www.delveinsight.com/report-store/cardiogenic-shock-market
Herpes Labialis Market- https://www.delveinsight.com/report-store/herpes-labialis-market
Meningococcal Meningitis Market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
Septic Shock Market- https://www.delveinsight.com/report-store/septic-shock-market
Transmucosal Drug Delivery Devices Market- https://www.delveinsight.com/report-store/transmucosal-drug-delivery-devices-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
Cone Rod Dystrophy Market- https://www.delveinsight.com/report-store/cone-rod-dystrophy-market
Orthopedic Power Devices Market- https://www.delveinsight.com/report-store/orthopedic-power-devices-market
Tendonitis Market- https://www.delveinsight.com/report-store/tendonitis-market
Diabetic Retinopathy Market- https://www.delveinsight.com/report-store/diabetic-retinopathy-market
Hydrocephalus Treatment Market- https://www.delveinsight.com/report-store/hydrocephalus-market
Short Bowel Syndrome Drug Market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
Spinal Trauma Devices Market- https://www.delveinsight.com/report-store/spinal-trauma-devices-market-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Tcr Therapy Market- https://www.delveinsight.com/report-store/tcr-therapy-market
Heart Failure Market- https://www.delveinsight.com/report-store/congestive-heart-failure-market
Surgical Robotic System Market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.